AmpliMed Corporation Announces Start of Randomized Phase 2 Trial of Amplimexon in Pancreatic Cancer
Published: May 01, 2008
TUCSON, Ariz.--(BUSINESS WIRE)--AmpliMed Corporation, a cancer therapeutics company, today announced that patient enrollment is underway in a Phase 2 trial of Amplimexon® (imexon for injection) in combination with gemcitabine (Gemzar®) in patients with advanced pancreatic cancer. Amplimexon, AmpliMed’s lead product candidate, is a chemotherapeutic that has demonstrated clinical and preclinical activity against a range of tumors. The trial is opening at clinical sites throughout the United States.